학술논문
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial
Document Type
Article
Author
Zhou, Qing; Chen, Ming; Jiang, Ou; Pan, Yi; Hu, Desheng; Lin, Qin; Wu, Gang; Cui, Jiuwei; Chang, Jianhua; Cheng, Yufeng; Huang, Cheng; Liu, Anwen; Yang, Nong; Gong, Youling; Zhu, Chuan; Ma, Zhiyong; Fang, Jian; Chen, Gongyan; Zhao, Jun; Shi, Anhui; Lin, Yingcheng; Li, Guanghui; Liu, Yunpeng; Wang, Dong; Wu, Rong; Xu, Xinhua; Shi, Jianhua; Liu, Zhihua; Cui, Na; Wang, Jingru; Wang, Qiang; Zhang, Ran; Yang, Jason; Wu, Yi-Long
Source
In The Lancet Oncology February 2022 23(2):209-219
Subject
Language
ISSN
1470-2045